MedPath

VANDERBILT UNIVERSITY MEDICAL CENTER

VANDERBILT UNIVERSITY MEDICAL CENTER logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1925-01-01
Employees
10K
Market Cap
-
Website
http://www.vumc.org

Clinical Trials

783

Active:58
Completed:407

Trial Phases

6 Phases

Early Phase 1:19
Phase 1:49
Phase 2:67
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (587 trials with phase data)• Click on a phase to view related trials

Not Applicable
370 (63.0%)
Phase 2
67 (11.4%)
Phase 4
65 (11.1%)
Phase 1
49 (8.3%)
Early Phase 1
19 (3.2%)
Phase 3
17 (2.9%)

AR Projections for Eye-gaze Evaluation in Phantoms

Not Applicable
Completed
Conditions
Kidney Stones
First Posted Date
2025-09-08
Last Posted Date
2025-09-08
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
8
Registration Number
NCT07161024
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Accelerated DMN-Targeted cTBS to Modulate DMN Connectivity

Not Applicable
Conditions
Schizophrenia
First Posted Date
2025-09-04
Last Posted Date
2025-09-11
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
40
Registration Number
NCT07155096
Locations
🇺🇸

Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States

Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial

Not Applicable
Not yet recruiting
Conditions
Postoperative Nausea
Postoperative Vomiting
First Posted Date
2025-09-03
Last Posted Date
2025-09-03
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
13120
Registration Number
NCT07152249
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

Not yet recruiting
Conditions
Inflammatory Bowel Disease (IBD)
Crohn&Amp;#39;s Disease (CD)
Ulcerative Colitis (UC)
Interventions
Drug: Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
First Posted Date
2025-08-14
Last Posted Date
2025-08-19
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
120
Registration Number
NCT07123350
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Effect of Rose Odor Exposure on Ictal Apnea

Not Applicable
Recruiting
Conditions
Epilepsy
Sudden Unexpected Death in Epilepsy
Interventions
Drug: 2-phenylethanol rose scent
First Posted Date
2025-08-11
Last Posted Date
2025-08-11
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
40
Registration Number
NCT07116421
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 156
  • Next

News

Ignite Proteomics Partners with Vanderbilt to Advance Breast Cancer Immunotherapy Biomarker Discovery

Ignite Proteomics and Vanderbilt University Medical Center have launched a one-year research collaboration to characterize protein-signaling pathways that help breast tumor cells evade immune system detection.

iMDx Digital PCR Platform Shows Equivalent Performance to NGS in Kidney Transplant Rejection Testing

iMDx's digital PCR-based GraftAssureIQ test demonstrated equivalent donor-derived cell-free DNA measurements compared to next-generation sequencing platforms in a head-to-head study of 96 kidney transplant recipients.

Bispecific Antibodies Show Superior Safety Profile and Efficacy in Follicular Lymphoma Treatment

Bispecific antibodies mosunetuzumab and epcoritamab demonstrate low rates of high-grade cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in follicular lymphoma patients.

Specialty Pharmacists Drive Significant Improvements in Non-MS Neurology Care, Study Shows

A single-center study at Vanderbilt University Medical Center found specialty pharmacists performed over 2,000 interventions across 741 neurology patients in just three months, with 98% of recommendations accepted by providers.

Climate Change and Neurological Health: Expert Highlights Critical Connections and Action Steps

Climate change directly impacts neurological health through air pollution and extreme heat, with particulate matter (PM2.5) linked to increased risk of stroke, dementia, and neurodevelopmental conditions.

Clinical Trial Diversity Crisis: Dr. Karen Winkfield Outlines Solutions for Inclusive Patient Participation

Clinical trial participation faces major barriers, with trial unavailability and lack of physician referrals identified as primary obstacles to patient enrollment in research studies.

UCSF Performs World's First OnQ Prostate-Assisted Robotic HIFU Procedure

Cortechs.ai and EDAP TMS SA achieved a milestone with the first-ever OnQ Prostate-assisted Focal One Robotic HIFU procedure performed at UCSF Prostate Center.

Novel Therapies Show Promise in Reshaping Frontline Metastatic RCC Treatment Landscape

Current immunotherapy and TKI combinations have significantly improved survival in metastatic RCC over the past decade, though treatment advances have reached a plateau.

AI-Driven Clinical Alert System Shows 10x Improvement in Suicide Risk Screening Rates

A Vanderbilt study demonstrates that AI-powered interruptive alerts led to 42% suicide risk assessment completion rate compared to 4% with passive alerts in neurology clinics.

Advances and Challenges in Hepatocellular Carcinoma (HCC) Treatment Highlighted in Recent Studies

Screening for HCC in patients with risk factors is associated with reduced mortality, emphasizing the importance of early detection.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.